IL1B and atherosclerosis: The results of the Canakinumab Anti‐Inflammatory Thrombosis Outcome Study (CANTOS) confirmed the role of vascular inflammation and IL‐β in atherosclerosis by demonstrating that the risk of recurrent cardiovascular events can be reduced with an IL‐1β‐neutralising antibody.17